Participation of peripheral tachykinin NK1 receptors in the carrageenan-induced inflammation of the rat temporomandibular joint.
Temporomandibular disorders represent one of the major challenges in dentistry therapeutics. This study was undertaken to evaluate the time course of carrageenan-induced inflammation in the rat temporomandibular joint (TMJ) and to investigate the role of tachykinin NK(1) receptors. Inflammation was induced by a single intra-articular (i.art.) injection of carrageenan into the left TMJ (control group received sterile saline). Inflammatory parameters such as plasma extravasation, leukocyte influx and mechanical allodynia (measured as the head-withdrawal force threshold) and TNFalpha and IL-1beta concentrations were measured in the TMJ lavages at selected time-points. The carrageenan-induced responses were also evaluated after treatment with the NK(1) receptor antagonist SR140333. The i.art. injection of carrageenan into the TMJ caused a time-dependent plasma extravasation associated with mechanical allodynia, and a marked neutrophil accumulation between 4 and 24h. Treatment with SR140333 substantially inhibited the increase in plasma extravasation and leukocyte influx at 4 and 24h, as well as the production of TNFalpha and IL-1beta into the joint cavity, but failed to affect changes in head-withdrawal threshold. The results obtained from the present TMJ-arthritis model provide, for the first time, information regarding the time course of this experimental inflammatory process. In addition, our data show that peripheral NK(1) receptors mediate the production of both TNFalpha and IL-1beta in the TMJ as well as some of the inflammatory signs, such as plasma extravasation and leukocyte influx, but not the nociceptive component.
Denadai-Souza
Alexandre
A
Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, SP, Brazil.
Camargo
Livia de Lucca
Lde L
Ribela
Maria T C P
MT
Keeble
Julie E
JE
Costa
Soraia K P
SK
Muscará
Marcelo N
MN
D000818:Animals; D002351:Carrageenan; D003627:Data Interpretation, Statistical; D005119:Extravasation of Diagnostic and Therapeutic Materials; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology*; D053583:Interleukin-1beta / Q000378:metabolism; D007958:Leukocyte Count; D008297:Male; D064729:Neurokinin-1 Receptor Antagonists; D010146:Pain / Q000209:etiology / Q000503:physiopathology; D009195:Peroxidase / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011812:Quinuclidines / Q000494:pharmacology / Q000627:therapeutic use; D019275:Radiopharmaceuticals; D051381:Rats; D017208:Rats, Wistar; D018040:Receptors, Neurokinin-1 / Q000502:physiology*; D012711:Serum Albumin, Radio-Iodinated; D013373:Substance P / Q000378:metabolism; D013705:Temporomandibular Joint Disorders / Q000139:chemically induced / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D053583:Interleukin-1beta; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D011812:Quinuclidines; D019275:Radiopharmaceuticals; D018040:Receptors, Neurokinin-1; D012711:Serum Albumin, Radio-Iodinated; D014409:Tumor Necrosis Factor-alpha; C085215:SR 140333; D013373:Substance P; D002351:Carrageenan; D009195:Peroxidase